4,5,6,11-tetrahydro-2H-pyrazolo[4',3':6,7]cyclohepta[1,2-b]indole | 1356957-79-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4,5,6,11-tetrahydro-2H-pyrazolo[4',3':6,7]cyclohepta[1,2-b]indole
• 英文别名: 4,5,6,11-tetrahydro-2H-pyrazolo[4',3':6,7]cyclohepta[b]indole；4,5,6,11-Tetrahydro-1h-Pyrazolo[4',3':6,7]cyclohepta[1,2-B]indole；3,4,17-triazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),2(6),4,11,13,15-hexaene
• CAS: 1356957-79-3；871112-61-7
• 化学式: C₁₄H₁₃N₃
• 分子量: 223.277
• InChiKey: HBWXPQZQCDQNND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  44.5
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  7-(hydroxymethylene)-7,8,9,10-tetrahydrocyclohepta[b]indol-6(5H)-one 在 一水合肼 作用下， 以 乙醇 为溶剂， 生成 4,5,6,11-tetrahydro-2H-pyrazolo[4',3':6,7]cyclohepta[1,2-b]indole
  参考文献：
  名称：

  A novel necroptosis inhibitor—necrostatin-21 and its SAR study

  摘要：

  An initial structure-activity relationship study of the novel necroptosis inhibitor Nec-21 was described. Any changes of the tetracyclic scaffold were detrimental for the activity. Introduction of a substituent to 7 or 8 position (e.g., cyano or methoxy group, respectively), would increase the activity. The 7 and 8-position disubstituted compound 17b was 35-fold as potent as the lead, while EC50 reached 14 nM. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.073

文献信息

• [EN] INDOLE DERIVATIVE AND USE FOR TREATMENT OF CANCER<br/>[FR] DÉRIVÉ D'INDOLE ET USAGE POUR LE TRAITEMENT DU CANCER
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2005118587A1

  公开（公告）日：2005-12-15

  The present invention relates to a compound represented by the formula (I’) wherein A is a benzene ring optionally having substituents, R1, R2a and R3 are each a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, R1 and R2a may form a ring via X, when R1 and R2a form a ring via X, R1 and R2a are each a bond or a divalent C1-5 acyclic hydrocarbon group optionally having substituents, and X is a bond, an oxygen atom, an optionally oxidized sulfur atom or an imino group optionally having a substituent, provided that R1, R2a and X are not bonds at the same time, or a salt thereof, and an agent for inhibiting kinase (phosphorylation enzyme), which contains this compound or a prodrug thereof. The compound of the present invention has an inhibitory activity against kinase such as a vascular endothelial growth factor receptor (VEGFR) and the like, and is useful as an agent for the prophylaxis or threatment of cancer and the like.

  本发明涉及一种由式(I')表示的化合物，其中A是一个苯环，可选地具有取代基，R1、R2a和R3分别是氢原子，可选地具有取代基的碳氢基团或可选地具有取代基的杂环基团，R1和R2a可以通过X形成环，当R1和R2a通过X形成环时，R1和R2a分别是键或可选地具有取代基的二价C1-5非环烃基团，X是键，氧原子，可选地氧化的硫原子或可选地具有取代基的亚胺基团，前提是R1、R2a和X不同时为键，或其盐，以及含有该化合物或其前药的抑制激酶（磷酸化酶）的药剂。本发明的化合物对激酶如血管内皮生长因子受体（VEGFR）等具有抑制活性，并可用作预防或治疗癌症等疾病的药剂。
• Indole Derivative and Use for Treatment of Cancer
  申请人：Nishikimi Yuji

  公开号：US20070254877A1

  公开（公告）日：2007-11-01

  The present invention relates to a compound represented by the formula wherein A is a benzene ring optionally having substituents, R 1 , R 2a and R 3 are each a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, R 1 and R 2a may form a ring via X, when R 1 and R 2a form a ring via X, R 1 and R 2a are each a bond or a divalent C 1-5 acyclic hydrocarbon group optionally having substituents, and X is a bond, an oxygen atom, an optionally oxidized sulfur atom or an imino group optionally having a substituent, provided that R 1 , R 2a and X are not bonds at the same time, or a salt thereof, and an agent for inhibiting kinase (phosphorylation enzyme), which contains this compound or a prodrug thereof. The compound of the present invention has an inhibitory activity against kinase such as a vascular endothelial growth factor receptor (VEGFR) and the like, and is useful as an agent for the prophylaxis or treatment of cancer and the like.

  本发明涉及一种化合物，其表示为以下式子： 其中，A是苯环，可选地具有取代基，R1、R2a和R3分别是氢原子、可选地具有取代基的碳氢基团或可选地具有取代基的杂环基团，当R1和R2a通过X形成环时，R1和R2a可以是一个键或可选地具有取代基的双价C1-5非环烃基团，X是键、氧原子、可选地氧化的硫原子或可选地具有取代基的亚胺基团，前提是R1、R2a和X不同时为键，或其盐，以及一种抑制激酶（磷酸化酶）的药剂，其含有该化合物或其前药。 本发明的化合物具有对激酶（如血管内皮生长因子受体（VEGFR）等）的抑制活性，可用作预防或治疗癌症等疾病的药剂。
• A Back-to-Front Fragment-Based Drug Design Search Strategy Targeting the DFG-Out Pocket of Protein Tyrosine Kinases
  作者：Hidehisa Iwata、Hideyuki Oki、Kengo Okada、Terufumi Takagi、Michiko Tawada、Yasushi Miyazaki、Shinichi Imamura、Akira Hori、J. David Lawson、Mark S. Hixon、Hiroyuki Kimura、Hiroshi Miki

  DOI：10.1021/ml3000403

  日期：2012.4.12

  We present a straightforward process for the discovery of novel back pocket-binding fragment molecules against protein tyrosine kinases. The approach begins by screening against the nonphosphorylated target kinase with subsequent counterscreening of hits against the phosphorylated enzyme. Back pocket-binding fragments are inactive against the phosphorylated kinase. Fragment molecules are of insufficient size to span both regions of the ATP binding pocket; thus, the outcome is binary (back pocket-binding or hinge-binding). Next, fragments with the appropriate binding profile are assayed in combination with a known hinge-binding fragment and subsequently with a known back pocket-binding fragment. Confirmation of back pocket-binding by Yonetani-Theorell plot analysis progresses candidate fragments to crystallization trials. The method is exemplified by a fragment screening campaign against vascular endothelial growth factor receptor 2, and a novel back pocket-binding fragment is presented.
• Synthesis, antimicrobial, antimycobacterial and structure–activity relationship of substituted pyrazolo-, isoxazolo-, pyrimido- and mercaptopyrimidocyclohepta[b]indoles
  作者：Ezhumalai Yamuna、R. Ajay Kumar、Matthias Zeller、Karnam Jayarampillai Rajendra Prasad

  DOI：10.1016/j.ejmech.2011.10.046

  日期：2012.1

  A new class of heterocycles, specifically substituted pyrazolo-, isoxazolo- and pyrimidocyclohepta[b]indoles, has been prepared by condensation of substituted 7-(hydroxymethylene)-7,8,9,10-tetrahydrocyclohepta[b]indol-6(5H)-ones with hydrazine hydrate, hydroxylamine hydrochloride, phenylhydrazine, urea and thiourea, respectively. The structures of the compounds were established by IR, H-1 NMR, C-13 NMR, mass spectral analysis, X-ray diffraction, and the compounds have been screened for in vitro antimicrobial and antimycobacterial against Mycobacterium tuberculosis H37Rv (MTB). Among the compounds screened, five substances were found to have an MIC of 3.12 mu g/ml or greater against MTB. Structure-activity relationship (SAR) analyses and in silico drug relevant properties (HBD, HBA, PSA, c Log P, M.wt) confirmed that the compounds are potential lead compounds for future drug discovery studies. (C) 2011 Elsevier Masson SAS. All rights reserved.